Abstract 52P
Background
We evaluated the relationship between 18F-FDG uptake and mitochondrial activity in cancer cells and investigated the prognostic implications thereof in patients with invasive ductal carcinoma of the breast (IDCB).
Methods
In total, 150 consecutive patients with IDCB who underwent preoperative 18F-FDG PET/CT followed by curative surgical resection were retrospectively enrolled. Mitochondrial activity of cancer cells was assessed based on translocase of outer mitochondrial membrane 20 (TOMM20) expression and cytochrome C oxidase (COX) activity. Pearson’s correlation analysis was used to assess the relationship between SUVmax of the primary tumour (pSUVmax) and mitochondrial activity. Clinicopathological factors, including pSUVmax, histological grade, expression of ER, PR, HER2, and TOMM20, and COX activity, were assessed for prediction of progression-free survival (PFS). The Kaplan–Meier method and Cox proportional hazards model were used for the survival analysis.
Results
Sixteen of the 150 subjects (10.7%) showed progression during the follow-up period. pSUVmax correlated significantly and positively with TOMM20 expression and COX activity. Univariate analysis revealed that pSUVmax, TOMM20 expression, COX activity, ER and PR status, and histologic grade were significantly associated with PFS. Multivariate analysis revealed a significant difference in pSUVmax (HR, 4.50; 95% CI, 1.43–14.17; P = 0.010).
Conclusions
There was a significant positive correlation between 18F-FDG uptake and mitochondrial activity of cancer cells in patients with IDCB. Increased 18F-FDG uptake and mitochondrial activity were significantly associated with a shorter PFS. Therefore, assessment of preoperative 18F-FDG uptake and post-surgical mitochondrial activity in patients with IDCB could be used as marker for prediction of PFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Choi Byung Wook (Daegu Catholic University Medical Center).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract